Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers

Conference Correspondent  - ESMO 2018

Germ-line mutations in BRCA1 or BRCA2 genes are implicated in approximately 15% of ovarian cancers.1 Although this subset of ovarian cancers is generally characterized by a good initial response to chemotherapy, 10-year survival is not different between those with BRCA1/2 mutations and noncarriers.2 In a retrospective analysis of 212 women with relapsed high-grade serous ovarian cancer between 2000 and 2014, Sokolenko and colleagues sought to further evaluate the distinguishing clinical features between hereditary and sporadic ovarian cancer.3

Of the included patients, 113 (53.3%) and 99 (46.7%) underwent complete primary or interval surgical debulking, respectively. Most women (n = 146; 68.9%) were negative for BRCA1/2 germ-line mutations, whereas 66 (31.1%) were carriers of BRCA1/2 mutations. As the investigators expected, the median platinum-free interval (PFI) in BRCA1/2 carriers was longer compared with sporadic cases (13.2 months vs 8.0 months; P <.001). Furthermore, the proportion of ovarian cancer cases with PFI >12 months was significantly higher among BRCA1/2 carriers (38/66 [58%]) compared with patients with sporadic disease (51/146 [35%]; P = .003).

Looking at relapse location, no statistical between-group difference was observed in the frequency of relapses to distant locations (P = .4). However, systemic recurrences (ie, multiple lesions) occurred significantly more frequently in sporadic cases (98/144 [68%]) compared with carriers of BRCA1/2 mutations (30/60 [50%]; P = .02) and were associated with a shorter PFI (P = .003). In addition, a greater proportion of BRCA1/2 mutation carriers than noncarriers could be subjected to local treatment (locoregional discrete recurrence with lymphatic/transcoelomic spread) (29/66 [44%] vs 45/146 [31%], respectively; P = .045).

Taken together, the results of this study indicate that ovarian cancers driven by BRCA1/2 are characterized by a more favorable mode of relapse than sporadic high-grade serous ovarian cancers.


References

  1. Pan Z, et al. Oncotarget. 2017;8(57):97657-97670.
  2. Huang YW. Medicine. 2018;97:2(e9380).
  3. Sokolenko AP, et al. ESMO 2018. Abstract 991P.
Related Items
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
A Phase 1b and Randomized Phase 2 Trial of Pazopanib with or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Maintenance Olaparib Following Platinum-Based Chemotherapy in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA1/2 Mutation: Results from the Phase 3 SOLO1 Trial
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 2 Trial of Combination Nivolumab and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
Association of PD-L1 Expression with Clinical Response to Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Meta-Analysis of PARP-Inhibitor–Associated Gastrointestinal and Hepatic Toxicities
Conference Correspondent  published on October 20, 2018 in ESMO 2018
A Phase 2 Study of Durvalumab, a PD-L1 Inhibitor, and Olaparib in Recurrent Ovarian Cancer
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Last modified: October 20, 2018